Ann: PBT434 presented at 13th International AD/PD Conference, page-5

Don't believe me, but as far as I can see nobody else is taking a metal homeostasis drug against Parkinsons, although ApoPharma from Canada is using a stronger chelator, currently in phase2 Fair Park 2 with Deferiprone.

"Our research includes conditions with generalized iron overload such as in patients who have repeated blood transfusions, as well as conditions where there is no generalized iron overload, only localized regions of slightly elevated iron or even intracellular mishandling of iron, leading to iron-induced pathology, including certain neurological disorders, such as Friedreich Ataxia, pantothenate kinase associated neurodegeneration and Parkinson's Disease."
https://clinicaltrials.gov/ct2/show/study/NCT02728843

They have already completed delayed start trial which identified differences between the groups ES(Early Start) and DS (Delayed Start) which may indicate disease modification.

[Patients who started DFP treatment immediately (the ES group) showed a significantly better motor performance at either 6 or 12 months than patients in the DS group. Moreover, the patients in the DS group showed a significant worsening in motor performance during the first 6 months on placebo; only during the following 6 months of DFP treatment did they show a relative improvement]
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060813/

Here is Deferiprone dog tox results
[Mortality observed in the four dogs of the 600 mg/kg group between days 7 and 12. Toxicity observed at doses ≥ 100 mg/kg which included anorexia, emaciation, decreased activity, hypothermia, salivation and tremors. At 14 days, decreased white cell counts and platelets were found in most animals at 200 and 400 mg/kg. Hypertrophy of adrenal glands and atrophy of testes observed in some animals at ≥ 400 mg/kg. No treatment related effects found at doses of 25 and 50 mg/kg.]
http://www.ema.europa.eu/docs/en_GB...tific_Discussion/human/000236/WC500022046.pdf



http://pranabio.com/wp-content/uploads/2016/04/Prana-Presentation_World-Orphan-Drug-Congress.pdf
Look at page 8 of this presentation to see where thr PBT434 stands re iron attraction compared to a-sin and Deferiprone. PBT434 attraction is just above a-syn, but only about half of the attraction of Deferiprone.